Global Gingivitis Treatment Market Expected to Reach USD 11.19 Billion by 2033, Driven by Increased Oral Health Awareness and Technological Innovations.
The global gingivitis treatment market, valued at USD 7 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 4.8% over the next decade. By 2033, the market is expected to reach approximately USD 11.19 billion. This growth is primarily driven by the rising prevalence of gum disease, increased awareness of oral health, and ongoing advancements in treatment products and technologies. From 2018 to 2022, the market experienced a CAGR of 3.2%, indicating consistent demand for effective gingivitis treatments.
Gingivitis is an inflammation of the gum tissue surrounding the teeth. If left untreated, it can lead to more serious oral health issues. The gingivitis treatment market encompasses a variety of products and services, including therapeutic mouthwashes, toothpastes, and advanced dental procedures aimed at reducing inflammation and promoting gum health.
With heightened investments in research and the development of more effective treatment options, the market is poised to provide improved solutions for managing gingivitis, enhancing oral health, and preventing the progression to more severe gum diseases worldwide.
Challenges Facing The Gingivitis Treatment Market
High Treatment Costs May Hinder Market Growth
Despite growing awareness of oral health, many individuals remain unaware of gum disease and available treatment options. This lack of awareness can limit demand for gingivitis treatment products and services.
Additionally, the cost of gingivitis treatments can pose a barrier, especially for those without insurance. This situation may restrict demand and make it difficult for companies to generate revenue.
Furthermore, companies in the gingivitis treatment market must adhere to regulatory requirements concerning product safety and effectiveness. This can be particularly challenging for smaller firms with limited resources. To thrive in this competitive landscape, companies must navigate these challenges by developing innovative products, building strong brands, and effectively communicating the benefits of their offerings.
Market Competition
Key players in the gingivitis treatment market include Fibrocell Sciences, Tolmar Inc., Eli Lilly & Company, Align Technology, Dentsply International, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Glidewell Laboratories, Orapharma, Kaken Pharmaceutical, and Valeant Pharmaceuticals International. These companies, along with various healthcare providers and technology firms, are significant contributors to the market.
In an exciting development, researchers at the University of Birmingham are working on a rapid test for gum disease.
Announced in October 2022, this probe is designed for use in dental surgeries and pharmacies. It aims to facilitate early detection of conditions such as heart disease, lung disease, type 2 diabetes, and rheumatoid arthritis.
Developed by Professor Tim Albrecht from the School of Chemistry and Dr. Melissa Grant from the School of Dentistry, the new technique allows for quick and accurate assessments of gum disease using saliva samples. The method employs a specialized probe and detector to measure biomarkers indicative of the presence and severity of gum disease.
These biomarkers were validated by the university’s Periodontal Research Group and published in the Journal of Clinical Periodontology earlier this year. The researchers have received funding from the EPSRC Impact Acceleration Account to create a prototype, which is expected to be launched within a year.
Related topics: